Chow brings with him more than 30 years’ experience in the life sciences industry, working with renowned companies such as Philips Healthcare, Boston Scientific, GE Healthcare, BD. In conversation with BioSpectrum Asia, Raymond Chow, Vice President- Asia Pacific, Cytiva shares details about his vision to take the brand to the next level.
What are the key drivers for you to join Cytiva? What “new air” do you hope to bring to Cytiva?
One of the major factors in my decision to join Cytiva was the allure of the biotech/biopharma sector, where so many technologies are being developed to address the need for new therapeutics that can serve the community at large. The merger of Pall Life Sciences and Cytiva forming the “new Cytiva” also possesses the portfolio and technical expertise that can address the needs of the industry to bring these therapeutics from bench to bedside. This is what excites me. As an experienced business veteran, I am also curious to apply the Danaher Business System (DBS) to create an environment where our people can bring their best to work, and help our customers bring lifechanging therapeutics to the wider community in the shortest time possible.
After the integration of Cytiva and Pall Life Sciences, what are the key strengths and challenges for the “new” company?
هذه القصة مأخوذة من طبعة BioSpectrum Asia May2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة BioSpectrum Asia May2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.